Domača stranMVIR • STO
add
Medivir AB
Prejšnji trg. dan.
2,76 kr
Dnevni razpon
2,71 kr - 2,83 kr
Letni razpon
2,33 kr - 4,71 kr
Tržna kapitalizacija
311,83 mio. SEK
Povprečni obseg
91,52 tis.
Razm. P/E
-
Dividendna donosnost
-
Primarna borza
STO
Borzne novice
Finančni podatki
Izkaz poslovnega izida
Prihodek
Čisti dohodek
| (SEK) | sep. 2024info | Sprememba L/L |
|---|---|---|
Prihodek | 900,00 tis. | 12,50 % |
Stroški poslovanja | 7,30 mio. | 5,80 % |
Čisti dohodek | −34,60 mio. | −46,61 % |
Čista dobičkovnost prihodkov | −3,84 tis. | −30,32 % |
Earnings per share | −0,30 | 28,57 % |
EBITDA | −35,30 mio. | −50,21 % |
Efektivna davčna stopnja | — | — |
Bilanca stanja
Skupna sredstva
Skupne obveznosti
| (SEK) | sep. 2024info | Sprememba L/L |
|---|---|---|
Denar. in kratkor. naložbe | 92,50 mio. | 51,39 % |
Skupna sredstva | 204,20 mio. | 15,96 % |
Skupne obveznosti | 62,40 mio. | 20,93 % |
Celoten lastniški kapital | 141,80 mio. | — |
Shares outstanding | 112,17 mio. | — |
Razmerje P/B | 2,19 | — |
Donosnost sredstev | −40,60 % | — |
Donosnost kapitala | −53,35 % | — |
Denarni tok
Neto sprememba denarnih sredstev
| (SEK) | sep. 2024info | Sprememba L/L |
|---|---|---|
Čisti dohodek | −34,60 mio. | −46,61 % |
Denar iz dejavnosti | −33,40 mio. | −59,05 % |
Denar iz naložb | — | — |
Denar iz financiranja | −600,00 tis. | 0,00 % |
Neto sprememba denarnih sredstev | −34,10 mio. | −57,14 % |
Prost denarni tok | −21,80 mio. | −71,32 % |
Vizitka
Medivir is a Swedish biotech company. Medivir focuses its research focus on oncology and particularly on innovative pharmaceuticals that meet substantial unmet medical needs. The pharmaceutical development work is conducted both in-house and through partnerships, usually with global pharmaceutical companies.
Medivir has a leading expertise in the design of protease inhibitors and in the science of nucleotides and nucleosides.
Medivir is listed on the Nasdaq Stockholm Mid Cap List.
In February 2020, Medivir announced that the company has signed a licensing agreement for Xerclear with Chinese company Shijiazhuang Yuanmai Biotechnology Co Ltd. The agreement gives SYB the right to register, manufacture and market the product in China. Wikipedia
Generalni direktor
Datum ustanovitve
1988
Spletno mesto
Zaposleni
10
